10Jul 2024
Eli Lilly's Mounjaro Outperforms Ozempic in Weight Loss Study.

Eli Lilly's Mounjaro Outperforms Ozempic in Weight Loss Study.

A head-to-head study published in JAMA Internal Medicine compared Eli Lilly's new weight loss drug, Mounjaro (tirzepatide), with Novo Nordisk's Ozempic (semaglutide). Analyzing data from over 18,000 US patients between May 2022 and September 2023, researchers found that Mounjaro led to significantly greater weight loss outcomes than Ozempic. Results showed higher percentages of patients achieving five percent, ten percent, and fifteen percent or greater weight loss with Mounjaro. Both drugs are GLP-I analogs that mimic a satiety hormone. The study highlights Mounjaro's efficacy edge over Ozempic in managing obesity, a critical health concern globally.

  • #general surgery
  • #pharmacology
  • #general medicine
  • #psych
  • #rheumatology
  • #pathology
  • #radiology
  • #anaesthesia
  • #psychiatry
  • #fmt
  • #emergency medicine
  • #academics
  • #nursing
  • #pharmacy
  • #trichology
  • #andrology
  • #orthopaedics
  • #critical care
  • #dermatology
  • #dentistry
  • #oncology
  • #business
  • #gastroenterology
  • #nephrology
  • #diagnostics
  • #urology
  • #ophthalmology
  • #gynaecology - ivf
  • #pediatrics
  • #neurology
  • #ent
  • #pulmonology
  • #family health
  • #cardiology
  • #endo-diabetology

Like

Save

Share